[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 61, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1032768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 61, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 735515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 57, "title": "Executive VP & CFO", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kristina  Engeseth", "title": "VP and Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 56, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 19.46, "open": 19.91, "dayLow": 17.26, "dayHigh": 20.5247, "regularMarketPreviousClose": 19.46, "regularMarketOpen": 19.91, "regularMarketDayLow": 17.26, "regularMarketDayHigh": 20.5247, "beta": 2.116, "forwardPE": -1.4740485, "volume": 421305, "regularMarketVolume": 421305, "averageVolume": 203000, "averageVolume10days": 709800, "averageDailyVolume10Day": 709800, "bid": 18.94, "ask": 19.63, "bidSize": 100, "askSize": 100, "marketCap": 68779848, "fiftyTwoWeekLow": 6.76, "fiftyTwoWeekHigh": 30.0, "priceToSalesTrailing12Months": 11.469043, "fiftyDayAverage": 10.2576, "twoHundredDayAverage": 15.2994, "currency": "USD", "enterpriseValue": 2990889, "floatShares": 419891, "sharesOutstanding": 3464200, "sharesShort": 121295, "sharesShortPriorMonth": 120036, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0352, "heldPercentInsiders": 0.17799, "heldPercentInstitutions": 0.48874, "shortRatio": 1.09, "shortPercentOfFloat": 0.0575, "impliedSharesOutstanding": 3587890, "bookValue": 15.067, "priceToBook": 1.2723169, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -76953000, "trailingEps": -7.25, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": 0.499, "enterpriseToEbitda": -0.032, "52WeekChange": 0.08412254, "SandP52WeekChange": 0.29098952, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ALGS", "underlyingSymbol": "ALGS", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "firstTradeDateEpochUtc": 1602855000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "bbc2c389-779c-3f10-ac5a-f071b0904bd5", "messageBoardId": "finmb_581475891", "gmtOffSetMilliseconds": -18000000, "currentPrice": 19.17, "targetHighPrice": 175.0, "targetLowPrice": 60.0, "targetMeanPrice": 103.33333, "targetMedianPrice": 75.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 74922000, "totalCashPerShare": 20.882, "ebitda": -92684000, "totalDebt": 9133000, "quickRatio": 3.575, "currentRatio": 3.809, "totalRevenue": 5997000, "debtToEquity": 18.231, "revenuePerShare": 1.005, "returnOnAssets": -0.67323, "returnOnEquity": -1.4669299, "freeCashflow": -49061000, "operatingCashflow": -84998000, "revenueGrowth": -0.608, "operatingMargins": -15.863669, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-16"}]